Spyre Therapeutics Completes Enrollment for SPY072 Phase 2 SKYWAY Trial, On Track for Q3/Q4 Data Readouts
SYRE has more than doubled off its 52-week low of $13.93.
Summary
Spyre Therapeutics announced the completion of enrollment for all sub-studies in its Phase 2 SKYWAY basket trial evaluating SPY072 (anti-TL1A) for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). This operational milestone confirms the company is on track for its planned '6 in '26' Phase 2 readouts, following recent positive data for SPY001 and a significant public offering in April. Completing enrollment is a key de-risking step in clinical development, demonstrating pipeline execution. Topline data for RA is expected in Q3 2026, with PsA and axSpA readouts anticipated in Q4 2026.
At the time of this announcement, SYRE was trading at $69.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $13.93 to $78.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.